Pathogenic DMD variants were found in 12.5% (5/40) of male probands with suspected X-linked dilated cardiomyopathy, mostly requiring specific assays for structural variants rather than gene panels.
Observational (n=40)
What is the diagnostic yield of multi-gene panel sequencing versus targeted structural variant assays for identifying DMD variants in males with primary DCM?
Primary genetic testing using multi-gene panels has a low yield for DMD-associated cardiomyopathy, necessitating specific assays for structural variants.
Background: Variants in the DMD gene, that encodes the cytoskeletal protein, dystrophin, cause a severe form of dilated cardiomyopathy (DCM) associated with high rates of heart failure, heart transplantation, and ventricular arrhythmias. Improved early detection of individuals at risk is needed. Methods: Genetic testing of 40 male probands with a potential X-linked genetic cause of primary DCM was undertaken using multi-gene panel sequencing, multiplex polymerase chain reaction, and array comparative genomic hybridization. Variant location was assessed with respect to dystrophin isoform patterns and exon usage. Telomere length was evaluated as a marker of myocardial dysfunction in left ventricular tissue and blood. Results: Four pathogenic/likely pathogenic DMD variants were found in 5 probands (5/40: 12.5%). Only one rare variant was identified by gene panel testing with 3 additional multi-exon deletion/duplications found following targeted assays for structural variants. All of the pathogenic/likely pathogenic DMD variants involved dystrophin exons that had percent spliced-in scores >90, indicating high levels of constitutive expression in the human adult heart. Fifteen DMD variant-negative probands (15/40: 37.5%) had variants in autosomal genes including TTN , BAG3 , LMNA , and RBM20 . Myocardial telomere length was reduced in patients with DCM irrespective of genotype. No differences in blood telomere length were observed between genotype-positive family members with/without DCM and controls. Conclusions: Primary genetic testing using multi-gene panels has a low yield and specific assays for structural variants are required if DMD -associated cardiomyopathy is suspected. Distinguishing X-linked causes of DCM from autosomal genes that show sex differences in clinical presentation is crucial for informed family management.
Johnson et al. (Wed,) conducted a observational in Primary dilated cardiomyopathy (n=40). Genetic testing was evaluated on Detection of pathogenic/likely pathogenic DMD variants. Pathogenic DMD variants were found in 12.5% (5/40) of male probands with suspected X-linked dilated cardiomyopathy, mostly requiring specific assays for structural variants rather than gene panels.